Search results

This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

Type

NICE guideline

Published

10 September 2018

This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

Type

NICE guideline

Published

15 January 2019

This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

Type

NICE guideline

Published

12 August 2019

This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

Type

NICE guideline

Published

16 October 2019

This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

Type

NICE guideline

Published

22 January 2020

This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.

Type

NICE guideline

Published

20 February 2018

This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

Type

NICE guideline

Last updated

23 July 2019

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

Type

NICE guideline

Last updated

25 July 2019

This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

Type

NICE guideline

Published

28 March 2018

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

Type

NICE guideline

Published

20 June 2018

This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.

Type

NICE guideline

Published

11 April 2018

This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

Type

NICE guideline

Published

03 October 2018

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Type

Highly specialised technologies guidance

Published

14 August 2019

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Type

Highly specialised technologies guidance

Published

09 October 2019

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency

Type

Highly specialised technologies guidance

Published

07 February 2018

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Type

Highly specialised technologies guidance

Published

10 October 2018

Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults

Type

Highly specialised technologies guidance

Published

21 October 2020

Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

Type

Highly specialised technologies guidance

Published

22 May 2019

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Type

Highly specialised technologies guidance

Published

27 November 2019

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults

Type

Technology appraisal guidance

Published

16 May 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Type

Technology appraisal guidance

Last updated

24 July 2018

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults

Type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma in adults

Type

Technology appraisal guidance

Published

11 April 2018

Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults

Type

Technology appraisal guidance

Published

18 April 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Type

Technology appraisal guidance

Published

25 April 2018

Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Type

Technology appraisal guidance

Published

04 July 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

18 July 2018

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults

Type

Technology appraisal guidance

Published

25 July 2018

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Type

Technology appraisal guidance

Published

01 August 2018

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in

Type

Technology appraisal guidance

Published

08 August 2018

Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF) in adults

Type

Technology appraisal guidance

Published

06 February 2018

Evidence-based recommendations on ixazomib (Ninlaro), with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults

Type

Technology appraisal guidance

Published

07 February 2018

Evidence-based recommendations on lesinurad (Zurampic) for treating chronic hyperuricaemia (too much uric acid/urate in blood) in adults with gout

Type

Technology appraisal guidance

Published

07 February 2018

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

Type

Technology appraisal guidance

Published

21 February 2018

Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

Type

Technology appraisal guidance

Published

07 March 2018

Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults

Type

Technology appraisal guidance

Published

14 March 2018

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Type

Technology appraisal guidance

Published

03 September 2018

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

Type

Technology appraisal guidance

Published

19 September 2018

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults

Type

Technology appraisal guidance

Published

03 October 2018

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Type

Technology appraisal guidance

Published

03 October 2018

Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults

Type

Technology appraisal guidance

Published

17 October 2018

Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

Type

Technology appraisal guidance

Published

14 November 2018

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Type

Technology appraisal guidance

Published

29 August 2018